Barclays Strengthens Leadership with the Appointments of Alexis de Rosnay and Jeff Ammerman

Barclays has announced the appointments of Alexis de Rosnay as Chairman of Healthcare Investment Banking and Jeff Ammerman as Global Head of Specialty Pharmaceuticals Investment Banking.

Mr. de Rosnay will be based in London, and is expected to join the bank in July. Mr. Ammerman will be based in San Francisco, and is expected to join the bank in August.

"Continuing to broaden our coverage footprint, especially in the life sciences sector, is one of our top priorities, and we are delighted to welcome Alexis and Jeff to our team,"said Mr. Landgarten."Alexis and Jeff are two of the most recognized leaders in the industry, and their industry relationships and expertise across advisory and capital markets transactions will immediately enhance our ability to deliver for clients."

Mr. de Rosnay has more than three decades of investment banking experience, of which the vast majority has been focused on serving life sciences clients across Europe. He was previously Vice Chairman of ODDO-BHF, a leading Franco-German financial services group, and was CEO of Canaccord Genuity Europe and Senior Executive Vice President of Canacord Genuity Group Inc.

He also led regional Investment Banking franchises and global Healthcare Investment Banking groups at Lazard, Lehman Brothers and JP Morgan. With a wealth of expertise across the industry, extensive client relationships, and a track record of growing businesses, Mr. de Rosnay will offer highly valuable perspectives to clients. He will join Barclays in July, and will be based in London.

Mr. Ammerman will join Barclays in August, and will be based in San Francisco. He joins from Piper Sandler & Co where he established and built that bank's Global Specialty Pharmaceuticals Investment Banking practice.

Throughout his more than two-decade career, Mr. Ammerman has played a lead role in growing franchises by expanding into new areas of the market and building strong relationships with public and private companies, financial sponsors and venture capital firms. His experience working with late- and commercial-stage biopharma, and generic and OTC pharmaceutical companies will add significantly to Barclays' strategically important pharma footprint.